Skip to content
Not Approved (US) Longevity & Mitochondrial

Visoluten

also known as: Retinal peptide bioregulator, Eye peptide preparation

The Khavinson retinal bioregulator preparation, marketed in Russia for age-related retinal change including macular degeneration support. Evidence base is Russian-language Khavinson-group studies. Not FDA- or EMA-approved.

A retinal-tissue-derived short peptide preparation in the Khavinson cytomedine series. Marketed in Russia for age-related retinal decline. Evidence for efficacy in age-related macular degeneration or diabetic retinopathy is limited to Russian-language studies from the Khavinson group and affiliated ophthalmology centers, with minimal methodological rigor by Western standards.

Mechanism of action

Proposed tissue-specific transcriptional modulation in retinal cells under the Khavinson bioregulator framework. Not mechanistically characterized at molecular-target resolution in peer-reviewed Western literature.

Primary uses

  • Age-related retinal aging support (Russian nutraceutical positioning)
  • Adjunct in age-related macular degeneration (Russian clinical positioning)
  • Adjunct in diabetic retinopathy (Russian clinical positioning)

Typical dosing

1–2 capsules 1–2 times daily in 20–30 day courses (oral)

Russian nutraceutical dosing. No controlled efficacy data.

Regulatory status

Not FDA- or EMA-approved. Russian nutraceutical status only.

References

  1. [review] Khavinson VK, et al. "Peptide bioregulators in geriatric ophthalmology." Vestn Oftalmol, 2008;124:55-58 (Russian).
  2. [review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149.

Related peptides

Epithalon

A synthetic pineal tetrapeptide from the Khavinson group (St. Petersburg) — the only peptide with published data claiming telomerase activation and telomere elongation in human cell models.

Endoluten

The Khavinson pineal bioregulator preparation, positioned as a "precursor/complementary" product to epithalon (the synthetic AEDG tetrapeptide). Marketed in Russia for neuroendocrine and circadian support in aging. Evidence base is Russian-language Khavinson-group studies with minimal independent replication.

Cerluten

A Khavinson lung-derived short peptide bioregulator sold in Russia as a cytomedine supplement for respiratory aging. Like the rest of the Khavinson short-peptide family, supporting evidence is almost exclusively Russian-language and of low methodological rigor by Western standards; no independent replication, no FDA or EMA status, and no controlled clinical data.

Guides & tools

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.